LONDON – A study of genetic variants in patients with life-threatening COVID-19 has shed light on the mechanisms that underpin severe disease, uncovered new drug targets and pointed to approved drugs, including JAK inhibitors and phosphodiesterase type 4 inhibitors, as therapies that could aid recovery.
Keeping you up to date on recent developments in diagnostics, including: Predicting breast cancer recurrence, Comparing SARS-CoV-2 PCR tests, Paying attention to the little guy in proteomics, Increasing biomarker reproducibility
Data presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) – held, of course, in cyberspace and not San Antonio this year – added to the evidence that adding Verzenio (abemaciclib, Eli Lilly and Co.) to endocrine therapy for up to two years benefited women with high-risk, early stage hormone receptor-driven and HER2-negative breast cancer.
Keeping you up to date on recent developments in orthopedics, including: Can we make bones heal faster?; Risk of serious complications during knee replacement 73% higher when a tourniquet is used; Exercise may protect bone health after weight loss surgery.
A multicenter in vivo Japanese "transomics" analysis led by scientists at the University of Tokyo has revealed previously unknown allosteric and genetic regulatory axes underlying the altered hepatic glucose-responsive metabolism seen in obesity.
Keeping you up to date on recent developments in oncology, including: New theranostic nanoparticle design combines DNA wireframe and Sgc8c aptamer; Bolting TLR agonist to antibody converts cold tumors; Rule-based screening for degraders; How stress disrupts tumor cell sleep; Combo treatment shows efficacy in treatment of ALL.
Keeping you up to date on recent developments in cardiology, including: Addressing concerns regarding pharmacogenetic testing; Improving the nation's heart health; Researchers reveal genetic abnormalities that cause brain aneurysms.
RSS
